Project Grant R34AT013246
Award Date 7/20/26
Completion Date 6/30/29
Dollars Obligated $371K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $170,640 on April 17, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The award funds development and feasibility testing of TOPMED (Toolkit for Optimal Pain Management in the Emergency Department), a mind-body intervention designed to reduce pain...
- The National Institute of Neurological Disorders and Stroke awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $3.637 million on August 24, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to identify pro-resolving lipid mediator receptors as therapeutic targets for endometriosis-associated pain. The project runs through April 30, 2030, and is performed in Massachusetts. The research aims to identify the most active specialized...
- The National Institute of Neurological Disorders and Stroke awarded the University of Florida $187,317 on July 20, 2026, to characterize the endometriosis microbiome and metabolomic pain phenotype under the Drug Use and Addiction Research Programs (CFDA 93.279). The project stratifies individuals with endometriosis into treatment-responsive groups by identifying differences in microbial and NAD+ metabolomic patterns associated with differing pain characteristics, quality of life, psychological...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- The National Institute of Allergy and Infectious Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $766,498 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 3, 2026. The award funds investigator-initiated research examining controlled self-reactive T cell responses in endometrial tissue physiology and reproduction. The research will determine whether endometrial T cell activation is locally driven by self-antigens, define how T...
- The National Institutes of Health Office of the Director awarded a Cooperative Agreement totaling $3.262 million to the Massachusetts Institute of Technology on February 6, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to establish the NAMS Technology Development Center for Women's Health, a translational research platform targeting gynecology disorders including endometriosis, adenomyosis, heavy menstrual bleeding, and polycystic ovary syndrome. MIT will develop combinatorial...
- The National Center for Complementary and Integrative Health awarded Massachusetts General Hospital (operating as The General Hospital Corporation) a Cooperative Agreement totaling $1,258,356 on August 5, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). Performance runs through July 31, 2027, with work performed in Boston, Massachusetts. The award funds the Toolkit for Optimal Recovery After Orthopedic Injury (TOR), a multi-site efficacy...
- The National Cancer Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $650,513 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on May 14, 2026 for development of a CRISPR-based sensitive liquid biopsy for endometrial cancer using tumor-derived hallmarks (CRISPR SLEUTH). The award is a Project Grant (R01CA310785). The research addresses endometrial cancer, which exhibits increasing incidence and mortality rates, with...
- The National Institute of Neurological Disorders and Stroke awarded The McLean Hospital Corporation $468,368 on September 5, 2026, to investigate the relationship between gut microbiome composition, multisensory sensitivity, and pain experience in adolescent girls with primary dysmenorrhea under CFDA 93.279 (Drug Use and Addiction Research Programs). The project will evaluate how alterations in gut microbiome composition contribute to multisensory sensitivity—heightened sensitivity to...
- The National Institute of Child Health and Human Development awarded Trustees of Tufts College $351,945 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate inflammation resolution mechanisms in endometrial health and disease. The research dissects how specialized pro-resolving mediators, a class of lipid-derived molecules that orchestrate inflammation resolution, operate in the human endometrium across the menstrual cycle. The...